Vaxcyte (PCVX) Free Cash Flow (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Free Cash Flow data on file, last reported at -$282.7 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 64.67% year-over-year to -$282.7 million in Q1 2026; TTM through Mar 2026 was -$774.1 million, a 60.63% decrease from a year earlier, with the FY2025 full-year figure at -$663.1 million, down 39.59% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$282.7 million, down from -$226.8 million in the prior quarter.
• Over the last five years, Free Cash Flow for PCVX reached as high as -$28.4 million in Q1 2022 and fell as low as -$282.7 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$112.0 million across 5 years, with a median of -$115.4 million in 2024.
• On a YoY basis, Free Cash Flow climbed as much as 20.09% in 2024 and fell as far as 209.2% in 2024.
• Year by year, Free Cash Flow stood at -$60.6 million in 2022, then tumbled by 138.23% to -$144.4 million in 2023, then gained by 20.09% to -$115.4 million in 2024, then sank by 96.5% to -$226.8 million in 2025, then dropped by 24.66% to -$282.7 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$282.7 million in Q1 2026, -$226.8 million in Q4 2025, and -$141.6 million in Q3 2025.